Company Analysis
Sign in

Molecular Partners AG (MOLN)

Nasdaq: MOLN · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.3
◀ Past 5.7● Present 5.4▶ Future 5.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

23 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Molecular Partners AG’s names, not what it holds today.

Patents granted
23
23 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against none in 2024 and 2 in 2023
Applications published
47
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology5
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Molecular Partners AG its own name
CH, as the owner printed on each patent
23 granted
13 published
MOLECULAR PARTNERS AG its own name
named as the applicant on its applications, in CH
0 granted
34 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 14, 202512,441,772Designed ankyrin repeat domain with improved stabilityBiotechnologyMolecular Partners AG
Oct 7, 202512,435,445Designed ankyrin repeat domains with altered surface residuesBiotechnologyMolecular Partners AG
Jun 17, 202512,331,090Multispecific proteinsBiotechnologyMolecular Partners AG
Dec 5, 202311,834,504DARPin based multi-specific t-cell engagersBiotechnologyMolecular Partners AG
Feb 14, 202311,578,427Designed ankyrin repeat domains with altered surface residuesBiotechnologyMolecular Partners AG
Oct 11, 202211,466,062Ankyrin repeat binding proteins and their usesPharmaceuticalsMolecular Partners AG
Sep 27, 202211,453,708Designed ankyrin repeat proteins binding to hepatocyte growth factorPharmaceuticalsMolecular Partners AG
May 17, 202211,332,501Recombinant binding proteins and their usePharmaceuticalsMolecular Partners AG
Jul 21, 202010,717,772Recombinant binding proteins targeting HER2 and serum albumin, and their usesPharmaceuticalsMolecular Partners AG
May 12, 202010,646,542Modified binding proteins inhibiting the VEGF-A receptor interactionPharmaceuticalsMolecular Partners AG
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0332297DLL3-SPECIFIC BINDING CONSTRUCTS AND THEIR USE IN RADIOTHERAPYPharmaceuticalsMOLECULAR PARTNERS AG
Mar 6, 20252025/0074994NOVEL DARPIN BASED CD70 ENGAGERSBiotechnologyMOLECULAR PARTNERS AG
Feb 6, 20252025/0042957DESIGNED REPEAT DOMAINS WITH DUAL BINDING SPECIFICITY AND THEIR USEPharmaceuticalsMolecular Partners AG
Sep 26, 20242024/0317852NOVEL DARPIN BASED CD33 ENGAGERSBiotechnologyMOLECULAR PARTNERS AG
Aug 22, 20242024/0279309RECOMBINANT CD40 BINDING PROTEINS AND THEIR USEBiotechnologyMOLECULAR PARTNERS AG
Aug 22, 20242024/0279290MULTISPECIFIC PROTEINSBiotechnologyMOLECULAR PARTNERS AG
Aug 1, 20242024/0254229NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERSBiotechnologyMOLECULAR PARTNERS AG
Jul 11, 20242024/0228545CHARGE MODIFIED DESIGNED REPEAT DOMAINS AND THEIR USEBiotechnologyMOLECULAR PARTNERS AG
Jun 13, 20242024/0190999MULTISPECIFIC PROTEINSBiotechnologyMOLECULAR PARTNERS AG
May 16, 20242024/0156980PROTEASE CLEAVABLE PRODRUGSPharmaceuticalsMOLECULAR PARTNERS AG
What it applied for, 2024 to 2025: Biotechnology 12 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MOLN · research, not advice